يعرض 1 - 9 نتائج من 9 نتيجة بحث عن '"Muriel X. G. Draht"', وقت الاستعلام: 0.42s تنقيح النتائج
  1. 1
    Academic Journal
  2. 2

    المساهمون: Clinical Genetics, Pathologie, RS: GROW - R2 - Basic and Translational Cancer Biology

    المصدر: Clinical Epigenetics, 13(1):80. BioMed Central Ltd.
    Clinical epigenetics, 13(1):80. BioMed Central Ltd
    Clinical Epigenetics
    CLINICAL EPIGENETICS

    وصف الملف: application/pdf

  3. 3
  4. 4

    المساهمون: Pathologie, Epidemiologie, RS: CAPHRI School for Public Health and Primary Care, RS: GROW - Oncology, RS: CAPHRI - Occupational Epidemiology, RS: CAPHRI - Clinical epidemiology, Radiotherapie, RS: GROW - R1 - Prevention, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, RS: GROW - R2 - Basic and Translational Cancer Biology, Pathology, Medical oncology, Surgery, CCA - Disease profiling

    المصدر: Molecular oncology, 8(3), 679-688. Elsevier
    Draht, M X G, Smits, K M, Tournier, B, Jooste, V, Chapusot, C, Carvalho, B, Cleven, A H G, Derks, S, Wouters, K A D, Belt, E J T H, Stockmann, H B A C, Bril, H, Weijenberg, M P, van den Brandt, P A, de Bruine, A P, Herman, J G, Meijer, G A, Piard, F, Melotte, V & van Engeland, M 2014, ' Promoter CpG island methylation of RET predicts poor prognosis in stage II colorectal cancer patients ', Molecular oncology, vol. 8, no. 3, pp. 679-688 . https://doi.org/10.1016/j.molonc.2014.01.011

  5. 5

    المساهمون: Department of patholgy [School of Oncology and Developmental Biology - Maastricht], School for Oncology and Developmental Biology [Maastricht] ( GROW ), Maastricht University [Maastricht]-Maastricht University Medical Center-Maastricht University [Maastricht]-Maastricht University Medical Center, Department of radiotherapy [School of Oncology and Developmental Biology - Maastricht], Registre Bourguignon des Cancers Digestifs, Lipides - Nutrition - Cancer (U866) ( LNC ), Université de Bourgogne ( UB ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon ( ENSBANA ) -Université de Bourgogne ( UB ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon ( ENSBANA ) -Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ), Service de Pathologie [CHU de Dijon], Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ), Zuyd University of Applied Sciences (Heerlen, Pays-Bas), Chemelot Innovation and Learning Labs (Geleen, Pays-Bas), Department of Epidemiology, GROW-School for Oncology and Developmental Biology, Maastricht University [Maastricht], Pathologie, RS: GROW - R2 - Basic and Translational Cancer Biology, Promovendi ODB, Epidemiologie, RS: GROW - R1 - Prevention, Radiotherapie, School for Oncology and Developmental Biology [Maastricht] (GROW), Maastricht University [Maastricht]-Maastricht University Medical Centre (MUMC), Maastricht University [Maastricht]-Maastricht University [Maastricht]-Maastricht University Medical Centre (MUMC), Lipides - Nutrition - Cancer (U866) (LNC), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon (ENSBANA)-Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon (ENSBANA)-Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon)

    المصدر: Clinical Epigenetics
    Clinical Epigenetics, BioMed Central, 2016, 8 (1), pp.44. 〈http://clinicalepigeneticsjournal.biomedcentral.com/articles/10.1186/s13148-016-0211-8〉. 〈10.1186/s13148-016-0211-8〉
    Clinical epigenetics, 8:44. BioMed Central Ltd
    Clinical Epigenetics, BioMed Central, 2016, 8 (1), pp.44. ⟨10.1186/s13148-016-0211-8⟩

    مصطلحات موضوعية: Male, 0301 basic medicine, MESH: Sequence Analysis, DNA, Bisulfite sequencing, Analytic sensitivity, MS-HRM, MESH : Aged, MESH : Promoter Regions, Genetic, Polymerase Chain Reaction, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, 0302 clinical medicine, MESH: DNA Methylation, MESH : Female, MESH : Proto-Oncogene Proteins c-ret, Promoter Regions, Genetic, MESH: CpG Islands, MESH : Polymerase Chain Reaction, Genetics (clinical), MESH: Aged, DNA methylation, MESH : Prognosis, Methylation, MESH : CpG Islands, Prognosis, pyrosequencing, 030220 oncology & carcinogenesis, MESH: Survival Analysis, Female, MESH : Colorectal Neoplasms, MESH : Sensitivity and Specificity, Colorectal Neoplasms, MESH : Male, [SDV.CAN]Life Sciences [q-bio]/Cancer, Biology, Sensitivity and Specificity, MESH: Proto-Oncogene Proteins c-ret, High Resolution Melt, MESH: Prognosis, 03 medical and health sciences, MESH: Promoter Regions, Genetic, Genetics, Humans, Molecular Biology, Aged, MESH: Humans, Research, MSP, Proto-Oncogene Proteins c-ret, MESH : Humans, MESH: Polymerase Chain Reaction, Sequence Analysis, DNA, Survival Analysis, Molecular biology, MESH: Sensitivity and Specificity, MESH: Male, 030104 developmental biology, Pyrosequencing, Illumina Methylation Assay, CpG Islands, Cancer biomarkers, Clinical sensitivity, Primer (molecular biology), MESH : Survival Analysis, RET, MESH: Female, MESH : DNA Methylation, MESH: Colorectal Neoplasms, Developmental Biology, MESH : Sequence Analysis, DNA

  6. 6
  7. 7

    المساهمون: Promovendi ODB, Pathologie, Epidemiologie, RS: GROW - Oncology, RS: GROW - R1 - Prevention, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, RS: GROW - R2 - Basic and Translational Cancer Biology, Internal medicine

    المصدر: Cleven, A H G, Derks, S, Draht, M X G, Smits, K M, Melotte, V, Van Neste, L, Tournier, B, Jooste, V, Chapusot, C, Weijenberg, M P, Herman, J G, De Bruïne, A P & Van Engeland, M 2014, ' CHFR promoter methylation indicates poor prognosis in stage II microsatellite stable colorectal cancer ', Clinical Cancer Research, vol. 20, no. 12, pp. 3261-3271 . https://doi.org/10.1158/1078-0432.CCR-12-3734
    Clinical Cancer Research, 20(12), 3261-3271. American Association for Cancer Research Inc.

    وصف الملف: application/pdf

  8. 8

    المساهمون: Pathology, CCA - Oncogenesis, Promovendi ODB, Pathologie, RS: GROW - School for Oncology and Reproduction

    المصدر: Epigenomics, 4(2), 179-194. Future Medicine Ltd.
    Draht, M X G, Riedl, R R, Niessen, H, Carvalho, B, Meijer, G A, Herman, J G, van Engeland, M, Melotte, V & Smits, K M 2012, ' Promoter CpG island methylation markers in colorectal cancer: the road ahead ', Epigenomics, vol. 4, no. 2, pp. 179-194 . https://doi.org/10.2217/EPI.12.9

  9. 9